Specialty Pharmacy

An immunomodulatory cytokine interacts with its receptors differently than other cytokines.

An obesity drug may reduce the risk of metastatic prostate cancer.

Top news of the day from across the health care landscape.

FDA seeks to change policies to ensure balance between the need to preserve access and ensure safety of appropriately compounded drugs for patients whose needs cannot be met by FDA-approved products.

Erenumab observed to reduce monthly migraine days.

Amanda Walker, CPXP, BSN, RN, Senior Vice President, Patient Experience, Heritage Biologics, discusses RXPX, the Pharmacy Patient Experience Certification.

Gene expression may lead to castration-resistant prostate cancer.

A multiple sclerosis drug may be used as a PET scan tracer agent to image demyelination.

Top news of the day from across the health care landscape.

Vector-based gene therapy shows efficacy treating glaucoma.

Sen Bill Cassidy, MD (R-LA), proposes legislation that would require hospitals to pass 340B savings on to patients.

Court invalidates patent for abiraterone acetate (Zytiga).

Limited access to gene therapies may impact Americans with rare cancers who live in rural areas.

Significant progress has been made with field of gene therapy over the past few decades.

High-grade cardiovascular adverse events are twice as common when patients with multiple myeloma are treated with carfilzomib.

Controlling cholesterol synthesis expression may reduce walking disability in patients with multiple sclerosis.

Top news of the day from across the health care landscape.

Novel HIV test combines the convenience of the saliva test with the reliability of the blood test.

Tanios Bekaii-Saab, MD, FACP, Mayo Clinic Cancer Center, talks about key takeaways from the phase 2 ReDOS clinical trial for specialty pharmacists.

Kohei Shitara, MD, Department of Gastrointestinal Oncology of National Cancer Center Hospital East, Japan, discusses the importance of the REVERCE clinical trial for specialty pharmacists.

Prior treatment with sorafenib followed by pembrolizumab (Keytruda) shows promising progression-free survival and overall survival in patients with advanced hepatocellular carcinoma.

Cetuximab (Erbitux) with pembrolizumab (Keytruda) shows promise in patients with mCRC.

Induction therapy shows the potential to achieve disease control in patients with locally advanced pancreatic cancer.

A novel CTC assay showed up to 88% accuracy detecting precancerous and cancerous colorectal lesions.

Nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy) induced responses in patients with heavily pretreated gastrointestinal stromal tumors.

The addition of ramucirumab did not improve overall survival in patients with HER2-negative gastric cancer.

Participants in the Transform Rheumatoid Arthritis Care program could save 5% on drug spend.

Greater use of substituting generic drugs could have a major impact on Medicare Part D spending.